GO:0042379 chemokine receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042379 (chemokine receptor binding) is a molecular function defined as binding to a chemokine receptor, with the synonym chemokine receptor ligand.
• Chemokine receptors are G protein-coupled receptors (GPCRs) that interact with chemokines through a two-step docking and activation mechanism involving the receptor N-terminus and extracellular loops.
• Atypical chemokine receptors (ACKRs) bind chemokines but do not signal through G proteins, instead scavenging ligands to shape chemokine gradients.
• The interaction between chemokines and their receptors is regulated by post-translational modifications, oligomerization, and interactions with glycosaminoglycans.
• Dysregulation of chemokine receptor binding contributes to cancer metastasis, inflammatory diseases, and neurodegeneration.
• CRISPR-based knockout, knock-in, and point-mutation models are essential for dissecting chemokine receptor binding specificity and downstream signaling.
Description
Chemokine receptor binding (GO:0042379) is a molecular function that describes the binding of a ligand to a chemokine receptor. Chemokines are a family of small cytokines that direct the migration of leukocytes and other cells by activating chemokine receptors, which are predominantly G protein-coupled receptors (GPCRs). This binding event is the first step in a signaling cascade that controls cell trafficking, immune surveillance, and development. The specificity of chemokine-receptor interactions is critical for proper immune function, and dysregulation leads to inflammatory diseases, cancer, and neurological disorders. Understanding the structural and mechanistic basis of chemokine receptor binding is therefore a major focus in immunology and drug discovery. Researchers study this term to identify how chemokines selectively engage their receptors, how atypical receptors scavenge ligands, and how mutations alter binding affinity and signaling. The availability of high-resolution structures and advanced modeling techniques has provided detailed insights into the dynamic interactions at chemokine-receptor interfaces.
chemokine receptor binding At A Glance
| GO ID | GO:0042379 |
|---|---|
| GO term | chemokine receptor binding |
| Ontology | molecular_function |
| Synonym | chemokine receptor ligand |
| Definition | Binding to a chemokine receptor. |
| Major function | Mediates chemokine-receptor interactions that trigger cell migration and activation. |
| Related receptors | CCR1-10, CXCR1-6, XCR1, CX3CR1, and atypical receptors ACKR1-4. |
| Related ligands | CC, CXC, XC, and CX3C chemokines. |
| Disease relevance | Inflammation, cancer metastasis, neurodegeneration, and immune disorders. |
What Is GO:0042379?
According to the Gene Ontology, GO:0042379 (chemokine receptor binding) is defined as the binding to a chemokine receptor. The term is classified under molecular_function and has the synonym chemokine receptor ligand. This function encompasses the physical interaction between a chemokine molecule and its cognate receptor, which typically initiates intracellular signaling. The binding can occur on the cell surface and may involve multiple contact sites, including the receptor N-terminus and extracellular loops.
Why Is chemokine receptor binding Important in Cell Biology?
Chemokine receptor binding is fundamental to immune cell trafficking, development, and host defense. It governs the directed migration of leukocytes to sites of inflammation and lymphoid organs, and it is exploited by pathogens and tumor cells to promote disease. The binding specificity determines which cells respond to which chemokines, and even single amino acid changes can alter receptor selectivity and signaling. Consequently, this function is a major target for therapeutic intervention in autoimmune diseases, cancer, and neurological disorders.
• Controls leukocyte trafficking and immune surveillance.
• Regulates inflammatory responses and tissue homeostasis.
• Involved in cancer metastasis and tumor microenvironment remodeling.
• Implicated in neurodegenerative diseases such as Alzheimer's disease.
• Essential for hematopoietic stem cell homeostasis.
• Targeted by viral chemokine binding proteins to evade immune responses.
• Provides structural insights for drug design against GPCRs.
• Atypical receptors scavenge chemokines to shape gradients.
• Mutations in chemokine receptors affect ligand binding and disease risk.
• CRISPR models enable functional dissection of binding specificity.
What Happens During chemokine receptor binding?
Chemokine presentation and receptor engagement
In simple terms: Chemokines are presented on cell surfaces or in the extracellular matrix, and they bind to receptors on target cells.
Chemokines are secreted proteins that form gradients to guide cell migration. They are often immobilized on glycosaminoglycans (GAGs) on endothelial cells or in the extracellular matrix, which facilitates their presentation to chemokine receptors on leukocytes. The binding of chemokines to GAGs can modulate their local concentration and oligomerization state, influencing receptor engagement. This presentation step ensures that chemokines act locally and directionally.
Two-step docking and activation
In simple terms: The chemokine first docks onto the receptor's N-terminus, then inserts into the receptor's transmembrane pocket to activate it.
Structural and modeling studies have revealed a two-step mechanism for chemokine receptor binding. The chemokine first interacts with the receptor N-terminus and extracellular loops, which provides affinity and specificity. This docking step is followed by insertion of the chemokine N-terminus into the transmembrane binding pocket of the receptor, triggering conformational changes that lead to G protein activation. This mechanism is supported by mutagenesis and structural data.
Receptor conformational changes and signaling
In simple terms: Once the chemokine binds, the receptor changes shape and activates intracellular signaling pathways.
Ligand binding induces conformational changes in the chemokine receptor, particularly in transmembrane helices, which facilitate coupling to heterotrimeric G proteins. This leads to downstream signaling cascades, including calcium mobilization, activation of Rho GTPases, and cell migration. The binding affinity and efficacy are determined by specific residues in both the chemokine and the receptor.
Atypical chemokine receptor binding and scavenging
In simple terms: Some receptors bind chemokines but do not signal; instead, they internalize and degrade them to shape gradients.
Atypical chemokine receptors (ACKRs) such as ACKR2 and GPR182 bind chemokines with high affinity but lack the canonical G protein signaling motifs. Instead, they act as scavengers, internalizing and degrading chemokines to maintain chemokine gradients and regulate immune cell trafficking. For example, ACKR2-V41A has decreased CCL2 binding and scavenging, which is associated with sustained inflammation and increased Alzheimer's disease risk. GPR182 is an endothelium-specific atypical receptor that maintains hematopoietic stem cell homeostasis.
Key Genes Involved in GO:0042379 chemokine receptor binding
The following genes encode chemokine receptors and related proteins that directly participate in chemokine receptor binding (GO:0042379).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCR5 | Binds CCL3, CCL4, CCL5; co-receptor for HIV | Target for HIV entry inhibitors and inflammatory diseases |
| CXCR4 | Binds CXCL12; regulates stem cell homing and metastasis | Target in cancer and WHIM syndrome |
| ACKR2 | Atypical receptor; scavenges CC chemokines | Linked to Alzheimer's disease risk and inflammation |
| GPR182 | Atypical receptor; maintains hematopoietic stem cell homeostasis | Endothelium-specific regulator |
| CCR2 | Binds CCL2; mediates monocyte recruitment | Target in atherosclerosis and neuroinflammation |
| CXCR3 | Binds CXCL9, CXCL10, CXCL11; Th1 responses | Autoimmune and transplant rejection |
| CCR7 | Binds CCL19 and CCL21; lymph node homing | Dendritic cell migration and cancer |
| CX3CR1 | Binds CX3CL1; leukocyte adhesion | Neurodegeneration and atherosclerosis |
| ACKR1 | Atypical receptor; binds Duffy antigen chemokines | Malaria resistance and inflammation |
| ACKR3 | Atypical receptor; scavenges CXCL12 | Cancer and development |
| ACKR4 | Atypical receptor; binds CC chemokines | Immune regulation |
| CCR1 | Binds CCL3, CCL5, CCL7 | Inflammation and cancer |
| CCR3 | Binds eotaxin; eosinophil recruitment | Asthma and allergy |
| CCR4 | Binds CCL17 and CCL22; Th2 responses | Atopic dermatitis and lymphoma |
| CXCR1 | Binds CXCL8; neutrophil activation | Inflammation and cancer |
| CXCR2 | Binds CXCL8; neutrophil recruitment | Chronic obstructive pulmonary disease |
| CXCR5 | Binds CXCL13; B cell homing | Autoimmunity and lymphoma |
How Is chemokine receptor binding Regulated?
Chemokine receptor binding is regulated at multiple levels. Post-translational modifications such as glycosylation and sulfation of receptor N-termini can modulate ligand affinity and specificity. Receptor oligomerization, including homodimers and heterodimers, can alter binding properties and signaling. Interactions with glycosaminoglycans on cell surfaces or in the extracellular matrix can concentrate chemokines and influence receptor engagement. Additionally, atypical chemokine receptors act as scavengers to regulate local chemokine availability, thereby indirectly controlling binding to signaling receptors. These regulatory mechanisms ensure precise control of immune cell migration and are often dysregulated in disease.
chemokine receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACKR2 | Alzheimer's disease; decreased CCL2 binding and scavenging | Knock-in of ACKR2-V41A in mice or human cell lines |
| GPR182 | Hematopoietic stem cell homeostasis | Endothelial-specific knockout in mice |
| CXCR4 | Cancer metastasis; WHIM syndrome | Knockout or point mutation in cancer cell lines |
| CCR5 | HIV infection; inflammatory diseases | Knockout in primary T cells or cell lines |
| CX3CR1 | Neurodegeneration; atherosclerosis | Knock-in of human variants in mice |
Chemokine receptor binding in cancer
Chemokine receptors such as CXCR4 and CCR7 are overexpressed in various cancers and promote metastasis by directing tumor cells to specific organs. The binding of chemokines to these receptors activates signaling pathways that enhance cell survival, proliferation, and migration. Targeting chemokine receptor binding with small molecule antagonists or antibodies is a promising therapeutic strategy.
Chemokine receptor binding in neurodegeneration
Atypical chemokine receptor ACKR2-V41A has decreased CCL2 binding and scavenging, leading to sustained inflammation and increased Alzheimer's disease risk. This highlights the importance of chemokine scavenging in neuroinflammation and neurodegeneration. Other chemokine receptors, such as CX3CR1, are also implicated in microglial function and neuronal survival.
Chemokine receptor binding in inflammatory and immune disorders
Dysregulated chemokine receptor binding contributes to chronic inflammatory diseases, including rheumatoid arthritis, asthma, and inflammatory bowel disease. For example, CCR2 binding to CCL2 mediates monocyte recruitment in atherosclerosis. Atypical receptors like GPR182 maintain hematopoietic stem cell homeostasis, and their dysfunction can lead to immune dysregulation.
From chemokine receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a specific chemokine receptor mediate ligand binding? | Knockout cell line (e.g., CRISPR-Cas9) followed by ligand binding assays |
| How does a point mutation affect binding affinity? | Point-mutation knock-in cell line (e.g., ACKR2-V41A) |
| What is the effect of receptor overexpression on signaling? | Overexpression cell line using lentiviral or CRISPR activation |
| Where is the receptor localized during binding? | Tagged knock-in (e.g., GFP or HA tag) for imaging |
| Which genes regulate chemokine receptor binding? | CRISPR library screening with readout for binding or migration |
| Can atypical receptors scavenge chemokines? | Knockout of ACKR in endothelial cells followed by chemokine degradation assays |
How to Study the chemokine receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Binding affinity (Kd) and receptor density | Characterizing mutant receptors |
| Surface plasmon resonance | Real-time binding kinetics (kon, koff) | Screening inhibitors |
| Cryo-EM | High-resolution structure of receptor-ligand complex | Mechanistic studies |
| Transwell migration | Cell migration in response to chemokine gradient | Functional validation of binding |
| CRISPR knockout screen | Genes required for chemokine receptor binding | Discovery of novel regulators |
| RNA-seq | Transcriptional changes upon receptor activation | Pathway analysis |
| Proteomics | Protein interactions and post-translational modifications | Identifying binding partners |
Binding assays
Radioligand binding assays, surface plasmon resonance (SPR), and isothermal titration calorimetry (ITC) are used to measure chemokine-receptor binding affinity and kinetics. These methods provide quantitative data on dissociation constants (Kd) and can be used to compare wild-type and mutant receptors.
Structural biology
X-ray crystallography and cryo-electron microscopy (cryo-EM) have provided high-resolution structures of chemokine receptors bound to ligands, revealing the molecular details of the binding interface. These structures are essential for understanding the two-step docking mechanism and for rational drug design.
Cell migration assays
Transwell migration and chemotaxis assays measure the functional consequence of chemokine receptor binding. Cells expressing specific receptors are placed in a gradient of chemokine, and migration is quantified. This method is widely used to study immune cell trafficking and cancer metastasis.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout or activation screens coupled with next-generation sequencing can identify genes that regulate chemokine receptor binding and downstream signaling. Bioinformatics tools are then used to analyze enrichment of sgRNAs and pathways.
How CRISPR Can Be Used to Study GO:0042379 chemokine receptor binding
Knockout
CRISPR-Cas9 knockout of chemokine receptor genes in cell lines or primary cells abolishes ligand binding and downstream signaling, allowing researchers to attribute specific functions to individual receptors. For example, knocking out ACKR2 in endothelial cells can reveal its role in chemokine scavenging.
Point Mutation
Introducing disease-associated point mutations, such as ACKR2-V41A, via CRISPR base editing or homology-directed repair enables precise assessment of how single amino acid changes affect chemokine binding affinity and scavenging activity.
Knock-in
Knock-in of tagged receptors (e.g., GFP or HA) allows visualization and quantification of receptor expression, trafficking, and binding in live cells. This approach is valuable for studying receptor localization and dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of chemokine receptors can amplify binding signals and facilitate biochemical assays, such as co-immunoprecipitation and structural studies. Overexpression models are also used to screen for agonist or antagonist activity.
How EDITGENE Supports chemokine receptor binding Research
Researchers studying chemokine receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand binding, signaling, or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for chemokine receptor binding research.
Frequently Asked Questions About chemokine receptor binding
What is GO:0042379?
GO:0042379 is the Gene Ontology term for chemokine receptor binding, a molecular function defined as binding to a chemokine receptor.
What genes are involved in chemokine receptor binding?
Genes encoding chemokine receptors such as CCR5, CXCR4, ACKR2, and GPR182 are directly involved in chemokine receptor binding.
What is the function of chemokine receptor binding?
It mediates the interaction between chemokines and their receptors, triggering cell migration, activation, and immune responses.
How does chemokine receptor binding work?
It involves a two-step mechanism: docking of the chemokine to the receptor N-terminus and extracellular loops, followed by insertion into the transmembrane pocket to activate signaling.
What diseases are associated with chemokine receptor binding?
Dysregulation is linked to cancer metastasis, Alzheimer's disease, inflammatory disorders, and immune deficiencies.
What are atypical chemokine receptors?
Atypical chemokine receptors (ACKRs) bind chemokines but do not signal through G proteins; instead, they scavenge ligands to shape gradients.
How can I study chemokine receptor binding?
Common methods include radioligand binding assays, surface plasmon resonance, cryo-EM, and cell migration assays.
What is the role of ACKR2 in Alzheimer's disease?
ACKR2-V41A has decreased CCL2 binding and scavenging, leading to sustained inflammation and increased Alzheimer's disease risk.
What is GPR182?
GPR182 is an endothelium-specific atypical chemokine receptor that maintains hematopoietic stem cell homeostasis.
How can CRISPR help study chemokine receptor binding?
CRISPR knockout, knock-in, and point mutation models allow precise manipulation of receptor genes to dissect binding mechanisms and disease relevance.
Conclusion
Chemokine receptor binding (GO:0042379) is a critical molecular function that governs immune cell trafficking, development, and disease. The two-step binding mechanism and the role of atypical receptors highlight the complexity and therapeutic potential of this interaction. CRISPR-based models are indispensable for dissecting the genetic and structural determinants of chemokine receptor binding, and EDITGENE provides the tools to accelerate such research.
References
- 1. Hughes CE et al.. 2018. A guide to chemokines and their receptors.. FEBS J 285(16):2944-2971 PMID: 29637711
- 2. Sonawani A et al.. 2022. Insights into the dynamic interactions at chemokine-receptor interfaces and mechanistic models of chemokine binding.. J Struct Biol 214(3):107877 PMID: 35750237
- 3. Rajagopalan L et al.. 2006. Structural basis of chemokine receptor function--a model for binding affinity and ligand selectivity.. Biosci Rep 26(5):325-39 PMID: 17024562
- 4. Lau EK et al.. 2004. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins.. Adv Protein Chem 68:351-91 PMID: 15500866
- 5. Murcia JDG et al.. 2020. Atypical chemokine receptor ACKR2-V41A has decreased CCL2 binding, scavenging, and activation, supporting sustained inflammation and increased Alzheimer's disease risk.. Sci Rep 10(1):8019 PMID: 32415244
- 6. Arimont M et al.. 2017. Structural Analysis of Chemokine Receptor-Ligand Interactions.. J Med Chem 60(12):4735-4779 PMID: 28165741
- 7. Le Mercier A et al.. 2021. GPR182 is an endothelium-specific atypical chemokine receptor that maintains hematopoietic stem cell homeostasis.. Proc Natl Acad Sci U S A 118(17) PMID: 33875597
- 8. Wedemeyer MJ et al.. 2019. Modeling the complete chemokine-receptor interaction.. Methods Cell Biol 149:289-314 PMID: 30616825
